Fuji Pharma (4554) · InitiativeRestated
Launch of 505(b)(2) Products in North America
First written in FY2020. 2 of 3 entries say "Restated". Latest entry: FY2022.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
North American Market Entry with 505(b)(2) ProductsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「The company will expand its business in North America through the launch of 505(b)(2) products in the U.S. market.」
It continues to pursue the policy of expanding its North American business through the launch of 505(b)(2) products in the U.S. - FY2021RestatedAnnual report
「The company will expand its business in North America through the launch of 505(b)(2) products in the U.S. market.」
It continues to pursue the policy of expanding its North American business through the launch of 505(b)(2) products in the U.S. - FY2020First statedAnnual report
「The company will expand its business in North America through the launch of 505(b)(2) products in the U.S. market.」
It describes, for the first time in concrete terms, the launch of 505(b)(2) products in the U.S. market as a means of entering the North American business.